Companies ›Healthcare ›ASND.O

ASND.O — NASDAQ Biotechnology

Asnd.O

$243,45

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

15,1B USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$243,45

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Ascendis Pharma A/S operates in the pharmaceuticals industry within the healthcare sector, focusing on biotechnology activities.

Business. Ascendis Pharma A/S operates in the pharmaceuticals industry within the healthcare sector, focusing on biotechnology activities.

Classification85 %

SectorHealth Care

Industry groupBiotechnology

Generated · model-assisted

Sell-side consensus

BUY18 analysts

18 buy0 hold0 sell

Avg 12m price target295,34

Analyst recommendations

18 analysts · consensus Buy

Buy18

Hold0

Sell0

12-month price target

295,34

Consensus of sell-side coverage.

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

18 analysts · indicative

Ownership→

T. Rowe Price Investment Management, Inc.

largest disclosed fund holder

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning ASND.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to ASND.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Ascendis Pharma A/S operates in the pharmaceuticals industry within the healthcare sector, focusing on biotechnology activities.

Classification85 %

SectorHealth Care

Industry groupBiotechnology

AI synthesis

GENERATED

(a) Capital structure and liquidity details are not available in the current dataset, as balance-sheet inputs are absent. Consequently, liquidity risk cannot be assessed, and no going-concern language is present in the source documents. The company has 61,977,408 basic and diluted shares outstanding.

(b) Profitability and return metrics are not provided in the valuation snapshot, preventing a comparison against cohort medians or industry benchmarks. The market capitalization is approximately $15.09 billion, with a market price of $243.45.

(c) Segment and geographic revenue mix data is absent from the input, so no analysis of revenue concentration or regional exposure can be performed.

(d) Historical revenue and net income trends are not available, precluding an assessment of the company's growth trajectory over the past five years or eight quarters.

(e) The risk assessment indicates low dilution risk, but liquidity risk remains unknown due to missing financial data. No other key flags are present.

(f) Recent analyst sentiment is strongly positive, with a mean recommendation of 1.50 (where 1 is strong buy), driven by 9 strong-buy and 9 buy ratings, and zero hold ratings. The mean price target is 295.34 EUR, with a median of 293.50 EUR, a high of 342.00 EUR, and a low of 255.00 EUR. Recent system logs indicate reconciler enqueue events for analysis jobs, but no specific news events or filing observations are detailed.

Key takeaways

Analyst sentiment is overwhelmingly bullish, with a mean recommendation of 1.50 and no hold ratings.
The mean price target of 295.34 EUR suggests significant upside potential from the current market price of $243.45.
Liquidity risk is unassessed due to the absence of balance-sheet data in the current snapshot.
Dilution risk is rated as low, with basic and diluted share counts being identical.
No historical financial performance data is available to evaluate growth trends or profitability.

Bull / Bear case

analysis pipeline

— missing data

In focus — financials by report

Valuation

Market price

$243,45

Market cap

$15.09B

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	14,26
Revenue	—no estimate	—no estimate	1,3B EUR
Operating income	—no estimate	—no estimate	322,0M EUR

Full-year consensus mean (period as reported by source) · consensus in EUR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Corporate eventM&A horizon

M&A probabilityconf 3 %

Probability

3 %

Base rate

3 %

Band

—

180-day horizon · target 2027-01-31 · 1,0× base rate

No acquirer candidates identified by the signal model.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution20 analysts

Strong buy10

Buy10

Hold0

Sell0

Strong sell0

12-month price target$310,42 · Median $306,00

Low $262,00High $370,92

Operating income · consensus322,0M EUR

EPS surprise

−126,4 %

reported vs consensus · miss

Revenue surprise

−46,3 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$255,00

Mean$295,34

Median$293,50

High$342,00

Spot$243,45

+21.3 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

M&A probabilityconf —

Probability

3 %

Base rate

3 %

Band

Low

180-day horizon · target 2027-01-31 · 1,0× base rate

No acquirer candidates identified by the signal model.

Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Reference data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Market Price
input from market-data provider (delayed close or quote-shim mid)
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Cap
market_price * shares_outstanding_diluted

Source documents

Ascendis Pharma A/S Market data — financials · 2026-08-04
reconciler_enqueue (reconciler) on ASND.O · 2026-08-04
Ascendis Pharma A/S Market data — analyst estimates · 2026-08-04

Ownership & reference

Top holders

T. Rowe Price Investment Management, Inc.Investment Managers · as of 2026-03-310,97 %$1M
American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,16 %$320M
MASSACHUSETTS FINANCIAL SERVICES CO /MA/Institutional Investor · as of 2026-03-310,14 %$426M
Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,11 %$205M
Capital Research Global InvestorsInvestment Managers · as of 2026-03-310,11 %$448M
FMR LLCInstitutional Investor · as of 2026-03-310,05 %$887M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,04 %$0M
AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,03 %$109M
AllianceBernstein L.P.Investment Managers · as of 2026-03-310,02 %$59M
Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,02 %$70M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,02 %$130M
Arrowstreet Capital, Limited PartnershipInvestment Managers · as of 2026-03-310,01 %$21M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,01 %$52M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,01 %$47M
First Trust Advisors L.P.Investment Managers · as of 2026-03-310,01 %$7M
Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$7M
AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$10M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$10M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$17M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$3M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$2M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$20M
Invesco QQQ TrustFunds · as of 2026-03-310,00 %$4M
Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$2M
Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$2M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$3M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$1M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$4M
AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$0M
Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$1M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$5M

Insider activity

Net selling7 buys · 1 sellsnet -$4,4M3 insiders · last 365d

SMITH SCOTT THOMASEVP & Chief Financial Officer · Ordinary SharesBought 100 @ $219,00$22K · 2026-06-02
BIENAIME JEAN JACQUESDirector · Ordinary SharesBought 200 @ $222,30$44K · 2026-05-29
BIENAIME JEAN JACQUESDirector · Ordinary SharesBought 200 @ $223,76$45K · 2026-05-29
BIENAIME JEAN JACQUESDirector · Ordinary SharesBought 100 @ $223,50$22K · 2026-05-29
SMITH SCOTT THOMASEVP & Chief Financial Officer · Ordinary SharesBought 250 @ $223,32$56K · 2026-05-29
BIENAIME JEAN JACQUESDirector · Ordinary SharesBought 200 @ $239,37$48K · 2026-05-26
BIENAIME JEAN JACQUESDirector · Ordinary SharesBought 200 @ $236,24$47K · 2026-05-26
JENSEN FLEMMING STEENSee Remarks · Ordinary SharesSold 19 460 @ $238,49$4,6M · 2026-05-11

Short positioning

3.1Mshares short-5.3% vs prior

5.61days to cover

59.5%short of daily vol

10.0Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

ASND.OCanonical

NASDAQ · USD

Intel & risk

PredictorM&A prob3 %Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread